

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories



Authors

The Polaris Observatory Collaborators

Graphical abstract

Adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

- In 18 countries the adjusted anti-HDV prevalence was lower than the published estimates
- In all but two countries (Canada and France), the HDV-RNA prevalence was lower than the literature anti-HDV prevalence
- China had the highest absolute number of HDV-RNA⁺ individuals



Highlights

- Previous studies have focused on the risk groups and regions that carry the highest HDV burden.
- HDV prevalence among people living with HBV in 25 countries/territories was often (18/25) lower than previous estimates.
- The highest prevalence was in Mongolia, but the largest absolute number of HDV-RNA⁺ individuals was in China.

Impact and implications

There is a great deal of uncertainty surrounding the prevalence of hepatitis delta virus among people living with hepatitis B virus at the population level. In this study, we aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower prevalence in the majority of places studied than had been previously reported. These data can help inform policy makers on the need to screen people living with hepatitis B virus to find those coinfecting with hepatitis delta virus and at high risk of progression, while also highlighting the pitfalls that other researchers have often fallen into.

Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

The Polaris Observatory Collaborators[‡]

Journal of Hepatology 2023. vol. ■ | 1–11

Background & Aims: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV-monoinfected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5–15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories.

Methods: We conducted a literature review to determine the prevalence of anti-HDV and HDV RNA in hepatitis B surface antigen (HBsAg)-positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV and HDV RNA prevalence in each country/territory at the population level.

Results: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the size of the HBsAg+ population and HDV RNA positivity rate, China had the highest absolute number of HDV RNA+ cases.

Conclusions: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence estimates. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV RNA+ individuals. The logistical and economic burden of reflex testing on the health system would be limited, as only HBsAg+ cases would be screened.

© 2023 The Author. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Globally, an estimated 258 million people were chronically infected with the hepatitis B virus (HBV) in 2022.¹ While only a fraction of these individuals are infected with hepatitis delta virus (HDV), robust epidemiology in the general population has remained limited. HDV is a satellite RNA virus that requires the HBV for assembly and entry of *de novo* viral particles.² While the HBV-monoinfected population are at risk of liver-related morbidity and mortality, HDV significantly increases liver disease progression.^{2,3} HDV has been demonstrated to accelerate the progression to liver failure or hepatocellular carcinoma (HCC), both of which contribute to early mortality.^{4,5} The risk of HCC has been found to be 3-fold higher in anti-HDV+ patients than HBV-monoinfected patients, with mortality being twice as high.⁶ In contrast to HBV monoinfection, control of HBV infection with nucleos(t)ide analogue therapy does not improve liver-related outcomes in patients infected with HDV.⁷

Recent studies have estimated the global prevalence of anti-HDV among the HBV-infected population at 5–15%.^{8–10} Two of these studies report high prevalence estimates and have been criticized for their wide inclusion criteria.^{11,12} The single study with a lower estimate of 4.5% has been criticized for not having wide enough inclusion criteria.¹³ While the study by Stockdale *et al.* aims to estimate the population-level prevalence of anti-HDV, unfortunately when calculating the global prevalence, the regional prevalence of HBV was used as opposed to the country-level HBV prevalence.⁹ This can have a major impact, particularly with respect to investigating countries with high HBV prevalence, but a relatively low HDV prevalence, such as China.

One of the challenges in attempting to estimate the population-level prevalence of HDV is the high level of bias inherent in most studies. There are few national serosurveys. Instead, most studies are performed either in risk groups or

Keywords: Hepatitis D; Hepatitis delta virus; Hepatitis B; Prevalence; Epidemiology; Viral hepatitis.

Received 8 August 2023; received in revised form 13 October 2023; accepted 30 October 2023; available online xxx

* Corresponding author. Address: Devin Razavi-Shearer, 1120 W South Boulder Rd, Suite 102, Lafayette, CO 80026, USA. (T): 720-890-4848, (F): 720-890-3817.

[‡] Full collaborators list is provided in Supplementary information.

<https://doi.org/10.1016/j.jhep.2023.10.043>



ELSEVIER

HDV prevalence in 25 countries/territories

among diagnosed individuals who are accessing care.¹⁴ Analyses in either of these groups lead to higher prevalence estimates than would be expected in the general population. This is further complicated by the fact that many regional serosurveys are performed in regions with high prevalence, again skewing estimates of HDV at the national population level. These biases are compounded by the lack of standardized tests for anti-HDV and the lack of HDV RNA data in many HBV studies.

Reflex testing, *i.e.* automatically testing all HBsAg+ specimens for anti-HDV at the laboratory level, is not performed nationally. Even with strong patient registry systems, the lack of reflex testing results in cases of HDV not being diagnosed. For example, recent data from centers in Spain indicate that the consistent implementation of reflex testing may increase the detection rate for HDV-infected cases by 8-10 times.¹⁵ Additionally, the prevalence reported in registry systems are likely to be overestimates, since testing only occurs among patients for whom HDV is suspected.

The current study aimed to overcome these inherent biases in the HDV data. This was accomplished by collecting all available data, and then working with in-country experts to find the optimal way to estimate the adjusted HDV prevalence in their country. This exercise was undertaken in 25 countries and territories.

Materials and methods

A comprehensive literature review was conducted for HDV (including detection of anti-HDV and HDV RNA) prevalence in 25 countries and territories. These papers were then scored and combined with a Delphi process which involved seeking out expert input to fill gaps and to confirm data when available.¹

The literature review was conducted in PubMed using the search terms “[Country Name] AND [(hepatitis d) or HDV] AND [prevalence]” and “[Country Name] AND (‘prevalence’/exp OR prevalence) AND (‘hepatitis D’/exp OR ‘hepatitis D’ OR ‘hdv’/exp OR ‘hdv’)”. Abstracts were reviewed for relevance, and only studies that included anti-HDV and/or HDV RNA prevalence were included. Grey literature, including, but not limited to, Ministry of Health reports, working papers, theses, conference presentations, local journals, and publications in local languages were also included in the analysis. Studies solely in non-representative populations (blood donors, people who inject drugs, hemophiliacs, ethnic groups, *etc.*) were excluded from the initial analysis. All studies considered after the exclusion criteria were applied can be found in the [supplementary information](#).

The results of the review were scored utilizing a multi-objective decision analysis approach, resulting in a score of 1–3 for each study, with 1 representing the lowest quality studies.¹ Once scored, two epidemiologists independently reviewed the literature in order to pick the most representative study ([supplementary information](#)).

After these data were collected, virtual meetings were held with experts from each setting to discuss the findings, collect additional information, and estimate the population-level prevalence of anti-HDV and HDV RNA positivity among the HBV-infected population (HBsAg+). These data were then combined with The Polaris Observatory HBV national data to estimate the population-weighted prevalence of anti-HDV and

HDV RNA in each country/territory at the general population level. The modeled HBV data account for historical and current prophylaxis measures, as well as the impact of treatment.¹⁶

The quantity and quality of data availability, combined with the known risk factors and drivers of HDV within each country/territory, necessitated additional country/territory-specific methods to estimate the prevalence at the population level.

Results

The results of the literature review and subsequent final estimate by country and territory can be found in [Table 1](#). Of the 25 countries/territories examined, 8 (Mainland China, Canada, Hong Kong, Republic of Korea, Mongolia, Pakistan, Türkiye, and the USA) had published studies that were agreed to be representative of the prevalence at the population level, 8 (Albania, Bulgaria, Brazil, Italy, Mexico, Portugal, Romania, and Spain) were based on weighted averages, 3 (Colombia, Israel, and Sweden) were based on notification data, 3 (France, Germany, and Taiwan) were based on unpublished data, and 3 (England, Japan, and Saudi Arabia) were based on expert opinion.

The highest anti-HDV prevalence among the HBV-infected population (HBsAg+) was recorded in Mongolia at 61.0% ([Table 1](#), [Fig. 1A](#)). However, once adjusted for the HBV+ population and HDV RNA positivity, due to the high burden of HBV, China had the highest absolute number of HDV RNA+ cases, represented by the largest blue circle ([Table 1](#), [Fig. 1A](#)). In order to better examine the differences between countries and territories, Pakistan and Mongolia were excluded from [Fig. 1B](#) since they have significantly higher burden.

None of the countries included have implemented national-level laboratory-based reflex testing following an HBsAg+ test.

The anti-HDV prevalence estimates were then utilized to calculate how many HBsAg+ individuals need to be tested to find one anti-HDV+ case. Results showed that Mongolia would only need to test 1.6 HBV+ individuals to find 1 anti-HDV+ case, but Hong Kong would need to test almost 667 individuals ([Table 1](#), [Fig. 2](#)).

Of the 25 countries and territories reported, 13 had general population estimates published in the 2020 article by Stockdale *et al.*⁹ The current study had higher estimates for France, Italy, Mongolia, and Pakistan but lower estimates for Brazil, Mainland China, England, Japan, Romania, and the USA when compared to Stockdale *et al.* ([Fig. 3](#)).⁹ The results in the current study and the aforementioned study for Germany, Türkiye and Saudi Arabia were similar.

By country

Albania

The highest scoring study from Albania reported an anti-HDV prevalence of 9.0% among patients admitted to a hospital in Tirana.¹⁷ Additional data were collected through discussions with the expert panel, and an overall anti-HDV prevalence of 3.3% was estimated by weighting the HBV-infected population by disease stage ([supplementary information](#)). The HDV RNA prevalence (in patients who were anti-HDV positive) was estimated to be 63% based on expert clinical experience.

Brazil

In Brazil, the prevalence of both HDV and HBV are highly dependent on the region in which an individual is from. While

Table 1. Anti-HDV and HDV RNA prevalence in 25 countries and territories.

Country/Territory	2023 HBsAg+	Literature % anti-HDV+	Adjusted % anti-HDV+	RNA+ cases	Adjusted HDV RNA+ prevalence	Adjusted HDV RNA+ cases	Anti-HDV tests to diagnose one case
Albania	183,000	9.0%	2.4%	4,400	62.5%	2,800	41.7
Brazil	1,025,000	3.2%	1.7%	17,400	75.3%	13,100	58.8
Bulgaria	169,000	8.6%	3.2%	5,400	80.0%	4,300	31.3
Canada	214,000	1.6%	3.0%	6,400	64.8%	4,100	33.3
China Mainland	78,548,000	1.2%	1.2%	942,600	66.6%	627,800	83.3
Colombia	302,000	5.2%	1.0%	3,000	69.9%	2,100	100.0
England	418,400	2.9%	1.0%	4,200	50.0%	2,100	100.0
France	142,000	1.8%	3.5%	5,000	75.0%	3,800	28.6
Germany	215,000	5.5%	3.0%	6,500	60.0%	3,900	33.3
Hong Kong	332,000	0.2%	0.2%	500	60.0%	300	666.7
Israel	129,000	6.5%	5.4%	7,000	47.0%	3,300	18.5
Italy	336,400	8.3%	3.4%	11,300	60.5%	6,800	29.7
Japan	926,000	8.5%	0.5%	4,600	40.8%	1,900	200.0
Korea, Republic of	1,360,000	0.3%	0.3%	4,100	54.0%	2,200	333.3
Mexico	116,000	2.4%	0.2%	300	69.9%	200	444.4
Mongolia	191,000	61.0%	61.0%	116,500	61.5%	71,600	1.6
Pakistan	3,762,000	16.6%	16.6%	624,500	85.0%	530,800	6.0
Portugal	110,000	12.6%	1.5%	1,700	72.9%	1,200	66.7
Romania	568,000	23.1%	2.9%	16,500	80.0%	13,200	34.5
Saudi Arabia	570,000	5.3%	4.0%	22,800	60.0%	13,700	25.0
Spain	208,000	5.2%	2.3%	4,800	72.9%	3,500	43.5
Sweden	31,000	3.8%	2.8%	900	75.0%	650	35.7
Taiwan	1,864,000	3.3%	0.9%	16,800	60.0%	10,100	111.1
Türkiye	1,962,000	2.8%	2.8%	54,900	68.0%	37,300	35.7
United States	1,650,000	6.0%	3.0%	49,500	66.0%	32,700	33.3

HDV, hepatitis delta virus.

many studies exist that provide estimates in the Amazon, a region with a high burden, fewer studies exist in the major population centers where the prevalence is quite low. The anti-HDV prevalence in the literature was found to be 3.2%. However, this was neither weighted by population nor HBV infections.¹⁸ A previous analysis using data from 2016 and 2017 found that 0.6% of 5 million rapid HBsAg tests conducted among 15-69-year-olds across Brazil were HBsAg+ positive. After adjusting for regional populations and factoring in cases from various special populations (prisoners, drug users, sex workers, men who have sex with men, patients with HIV, patients on dialysis, army conscripts and indigenous peoples), the HBsAg+ prevalence among 15-69-year-olds was estimated to be 0.8%.¹⁹⁻²⁹ This was then combined with the regional estimates from the aforementioned published study to estimate an anti-HDV prevalence of 1.7%.¹⁸ The details of these calculations can be found in the [supplementary information](#). Based on Ministry of Health data, it was assumed that HDV RNA prevalence was 75%.³⁰

Bulgaria

In Bulgaria, the only published study was conducted among patients with chronic liver disease in 1985, reporting an anti-HDV prevalence of 8.6%.³¹ Recent unpublished clinical data provided by the expert panel was utilized to weigh the infected population by disease stage, resulting in an anti-HDV prevalence of 3.2% ([supplementary information](#)). The HDV RNA prevalence was estimated to be 80% based on unpublished clinical data.

Canada

Data were sparse for Canada, with an anti-HDV estimate of 1.6% from a 1986 study conducted in Western Canada.³² After

discussions with the expert panel, it was agreed upon to use the largest study to date, which is based on specialist referral testing to the National Microbiology Laboratory, and reports an anti-HDV prevalence of 3.0% from 2020-2021.^{33,34} The HDV RNA prevalence was assumed to be 65% based on published national notification data.³³

China, Mainland

In China, a study based on the national HBV serosurveys in 2006 and 2008 found an anti-HDV prevalence of 1.2%.³⁵ This was agreed to be representative by the expert panel. Based on their clinical experience, the expert panel estimated the HDV RNA prevalence to be 67%.

Colombia

The literature review resulted in one study with an anti-HDV prevalence of 5.2%.³⁶ However, this study was not representative of the general population, as it was conducted in higher prevalence regions as well as among risk groups such as indigenous peoples. There is a high heterogeneity of HBV and HDV infections in Colombia. We estimated HDV prevalence by dividing the number of delta patients under care in the public system (RIPS) by the number of HBV-infected individuals diagnosed (SIVIGILA).^{37,38} The anti-HDV prevalence was found to be 1% (CI 0.6-1.2%). The expert panel estimated an anti-HDV prevalence of ~1% based on their clinical experience. The HDV RNA prevalence was estimated to be 70% based on a published study from the Amazon.³⁹

England

A Public Health England reported an anti-HDV prevalence of 2.9% from their sentinel surveillance system.⁴⁰ We estimated

HDV prevalence in 25 countries/territories




Fig. 1. HBsAg positivity, anti-HDV positivity and HDV RNA+ cases. (A) HBsAg positivity, anti-HDV positivity and HDV RNA+ cases in 25 selected countries and territories. (B) Excluding Pakistan and Mongolia. HBsAg, hepatitis B surface antigen; HDV, hepatitis delta virus.




Fig. 2. Number of anti-HDV tests needed to find one positive case. HDV, hepatitis delta virus.




Fig. 3. Comparison of anti-HDV prevalence in current study and Stockdale 2020. HDV, hepatitis delta virus.

an anti-HDV prevalence of 1% and an HDV RNA prevalence of 50% based on expert clinical experience.

France

In 2011, a large study among blood donors found an anti-HDV prevalence of 2.0% in France.⁴¹ When the data was discussed with the expert panel, it was found that over 30 centers in France participate in anti-HDV surveillance. The data from these centers indicate an anti-HDV prevalence of 3.5% and an HDV RNA prevalence of 75%.

Germany

The anti-HDV prevalence in Germany was initially estimated to be 5-6% based on two previously published studies.^{42,43} Clinical experience and unpublished single-center data were used to estimate an anti-HDV prevalence of 3% in Germany. Based on expert clinical experience, the HDV RNA prevalence was estimated to be 60%. However, the ongoing migration

movement (e.g., due to the war in Ukraine), which may substantially impact HDV prevalence in Germany has not been factored into these estimates.

Hong Kong

HDV prevalence is known to be quite low in Hong Kong. The highest scoring study was a territory-wide assessment conducted between 2015-2016 which found a 0% prevalence among 803 HBV+ individuals.⁴⁴ In order to quantify prevalence, we used an older study based on data collected between 1988 and 1990 which found a prevalence of 0.15%.⁴⁵ The HDV RNA prevalence was estimated to be 60% based on clinical experience.

Israel

In Israel, the literature reported an anti-HDV prevalence of 6.5% among patients with HBV.⁴⁶ Based on data from the Clalit Health Services, which covers 52% of the Israeli population,

HDV prevalence in 25 countries/territories

the anti-HDV prevalence is 5.4% and the HDV RNA prevalence was estimated to be 47%.

Italy

Italy has a number of high-quality cohort studies among patients. The literature reports an anti-HDV prevalence of 8.3%.⁴⁷ However, since this study was conducted among a cohort of patients under care, this estimate needs to be weighted by the size of the population at the given disease stage. The anti-HDV prevalence estimates by stage of disease from these studies were combined with the Italian HBV PRoGReSs Model outputs, to estimate an anti-HDV-weighted average of 3.4% (supplementary information).^{1,47,48} Based on data from the PITER cohort, the HDV RNA prevalence was estimated to be 61%.⁴⁹

Japan

In Japan, anti-HDV prevalence was found to be 8.5% in one study on a single small island.⁵⁰ However, discussions with experts revealed that prevalence from this island is not representative of the national HDV prevalence in Japan. Expert consensus centered on an anti-HDV prevalence of 0.5%. The HDV RNA prevalence was estimated to be 41%.⁵⁰

The Republic of Korea

In Korea, the anti-HDV prevalence of 0.3% from the literature was agreed to be representative by the expert panel.⁵¹ The HDV RNA prevalence was assumed to be 54% based on expert consensus.

Mexico

In Mexico, the highest scoring study found a prevalence of 2.4%.⁵² However, once it was reviewed with the experts, it was agreed that this figure was only representative of patients with cirrhosis under care. Thus, a weighted average based on disease stage was calculated resulting in an anti-HDV prevalence of 0.2% (CI 0.2-0.3%). The HDV RNA prevalence was assumed to be 70% based on expert clinical experience.

Mongolia

While many studies on HDV exist in Mongolia, the highest scoring study found an anti-HDV prevalence of 61.0% and an HDV RNA prevalence of 61.5% in 123 apparently healthy HBV-positive adults.⁵³

Pakistan

The highest scoring study found an anti-HDV prevalence of 16.6%, although it was among patients visiting a tertiary hospital for liver-related symptoms. Similar prevalence has been found in a serosurvey conducted in Punjab.⁵⁴ Based on data from clinics around the country, it was estimated that the HDV RNA prevalence was 85%.

Portugal

In Portugal, an anti-HDV prevalence of 12.6% was found among diagnosed patients attending a hepatology clinic.⁵⁵ This value was deemed far too high by the expert panel, since there is believed to be a geographic component to the distribution of HDV in Portugal, driven by immigration. Based on unpublished studies, an anti-HDV prevalence of 1% was applied to the North of Portugal and the city of Lisbon. A range of 3-14% was

found in unpublished studies, and so a point estimate of 5% was assumed to be representative of the South of Portugal (supplementary information). This results in an overall anti-HDV prevalence of 1.5%. We arrived at an HDV RNA prevalence of 73% based on expert consensus.

Romania

In Romania, the most prominent study reported an anti-HDV prevalence of 23.1%.⁵⁶ Discussions with experts revealed this to be representative of individuals who were hospitalized for HDV in 2011, and so would have already progressed to cirrhosis or a later disease stage. A national serosurvey is currently underway in the country, and the preliminary results from 20,000 individuals screened found an anti-HDV prevalence of 1% among the HBV-infected population. We applied the 23.1% prevalence to the population with cirrhosis or later stage disease in the Romanian PRoGReSs model, and the 1% prevalence to all other patients to get an overall weighted anti-HDV prevalence of 2.9%. Based on clinical experience, HDV RNA prevalence was estimated to be 80%.

Saudi Arabia

In Saudi Arabia, the literature reported an anti-HDV prevalence of 5.3%.⁵⁷ Based on expert opinion and clinical experience, it was estimated that the anti-HDV prevalence was 4%. HDV RNA prevalence was estimated to be 60% based on a 2017 publication.⁵⁷

Spain

A 2020 study in Spain found an anti-HDV prevalence of 5.2% among 2,888 patients in teaching hospitals.⁵⁸ Spain also recently published a large national serosurvey to estimate the prevalence of HDV. However, there were concerns that the study did not consider the prevalence among specific risk groups such as sex workers, HIV+ individuals, prisoners, injection drug users, and immigrants from Africa. We applied the serosurvey data to the Spanish population less the risk groups, for whom different prevalence estimates were applied, to reach an overall anti-HDV prevalence of 2.3% (supplementary information). HDV RNA prevalence was estimated to be 73% based on a published patient cohort.⁵⁸

Sweden

In Sweden, a study conducted between 1997-2008 estimated that 3.8% of the population accessing healthcare for chronic HBV were positive for anti-HDV.⁵⁹ National notification data from 1990 to 2021 for individuals with residency status and an identification number reported an anti-HDV prevalence of 2.0% and an HDV RNA prevalence of 75%. Based on their clinical experience, Swedish experts believe anti-HDV prevalence might be higher in the migrant population without residency status. An undiagnosed population of approximately 200-300 HDV RNA+ Mongolian migrants are believed to live in the Stockholm region. An anti-HDV prevalence of 2.8% has therefore been estimated.

Taiwan

Two hospital-based studies found an anti-HDV prevalence of 4.4% in Taiwan.^{60,61} Other data such as the older REVEAL cohort data and recent Taiwan Biobank data were also reviewed.⁶² Based on the triangulation of these sources, the

anti-HDV prevalence was estimated to be 0.9% in Taiwan, with an HDV RNA prevalence of 60%.

Türkiye

In Türkiye, an anti-HDV prevalence of 2.8% was found among 5,533 volunteers screened between 2009-2010.⁶³ This was deemed to be representative of the national prevalence by the expert panel. The HDV RNA prevalence was assumed to be 68%, based on a study among blood donors in South-eastern Türkiye.⁶⁴

USA

In the United States, the 1999-2012 National Health and Nutrition Examination Survey reported an anti-HDV prevalence of 6%.^{65,66} The expert panel came to a consensus, supported by data from Veteran's Affairs and electronic medical records, that the overall anti-HDV prevalence in the USA is approximately 3%.^{67,68} Based on clinical experience, it was estimated that the HDV RNA prevalence was 66%.

Discussion

Many published HDV prevalence studies are conducted among groups who have a higher probability of being infected with HDV, such as patients in tertiary care centers, specific risk groups, or high-prevalence regions. When available data are weighted by population size at the national level, the HDV prevalence often decreases. Thus, literature reviews may result in a higher prevalence estimate than is likely to be seen in the general population. Our approach in this study focused on leveraging the best available HDV data in a country or territory in order to determine the best possible estimate at the national/territorial population level. However, there is a vast heterogeneity in the type of data available and the most common, anti-HDV+ data, is a poor marker of active HDV infection as evidenced by the wide variance (40%-85%) in HDV RNA positivity rates. Although new treatments have become available in some regions, HDV continues to be neglected in research and as a priority in public health policy setting. For example, the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections mention the need to increase awareness, diagnostics, and treatment options for HDV, but define no indicators to be measured and set no targets.⁶⁹ Thus, there is clearly a strong need to improve medical education among physicians and nurses regarding this disease and the significant associated morbidity among infected individuals.

A couple of different factors drove high prevalence in countries like Brazil, Mainland China, England, Japan, Romania, and the USA which, in the study by Stockdale and co-authors, reported higher percentages compared to the current study.⁹ Brazil, Mainland China, and Japan all have regions with substantially higher prevalence of HDV than the national/territorial average. While these high-prevalence regions are important and should be part of elimination efforts, they are small in terms of population size and thus do not have a large impact on the national/territorial prevalence at the population level.

In England, the published sentinel surveillance data came from high-risk groups and are not representative of what clinicians see in their practice. This explains the lower prevalence presented here. Meanwhile, the national study from the USA has a very small sample size: 168 ([supplementary information](#)). Thus,

other studies with larger sample sizes were chosen to be more representative and in line with what is seen by clinicians.

The studies cited for the general population in Romania in the Stockdale 2020 study were both 0%. We assumed that the prevalence among hospitalized patients was also considered, thus leading to the overestimate in Stockdale.

The estimates for France, Italy, Mongolia, and Pakistan in the current paper were higher than those reported by Stockdale 2020.⁹ In France, the expert panel agreed that the national study was not representative of what they see clinically. For Italy, our study used a weighted average of prevalence by disease stage, whereas Stockdale used an undefined weighting system that appears to be similar to that which they used for Romania. There exists a great deal of uncertainty in the HDV prevalence in Mongolia and Pakistan, with the local experts agreeing that the estimates in our paper are representative of the current data.

The current approach allowed for the collection and reporting of data for countries and territories that have not been included with specific general population data in previous analyses. The flexible approach that was undertaken is a strength of the study; however, it can also be a limitation as the exact same populations are not being utilized and compared across countries and territories. While anti-HDV and HDV RNA positivity were the indicators utilized, there exist many different diagnostics with varying sensitivity and specificity. This likely contributes to the wide variability in the reported proportions of anti-HDV+ cases that are HDV RNA+ and can result in heterogeneity between estimates within a country or territory. These differences may also be due to the predominate modes of transmission in a country, as adults who acquire HBV and HDV simultaneously have a much higher probability of clearing both viruses when compared to individuals who acquire HDV via superinfection.⁷⁰

Another limitation of this study is that none of the countries and territories included were in sub-Saharan Africa or the Pacific Island countries. Both of these regions have had reports of high anti-HDV prevalence that require additional investigation.

Additional research is necessary to better understand the burden of HDV on the total population at the national/territorial level. However, while HBV and HDV serosurveys in the general population can provide strong insights, there is already a large population of HBV-diagnosed individuals, some of whom may be infected with and progressing from HDV. Implementing laboratory reflex testing would increase the knowledge base on HDV prevalence, while also allowing for earlier identification and linkage to care for HDV RNA+ individuals.⁷¹ While this method would not overcome the bias towards a higher prevalence in the absence of a national screening program, as those being diagnosed with hepatitis B are often more likely to have already progressed to later liver disease stages and thus are more likely to be infected with HDV. It would, nonetheless, overcome the major shortcoming currently inherent in notification systems. Since this intervention would only be testing those who are already found to be HBsAg+, the cost would be much lower than a national serosurvey and thus an approach scalable to many different countries and resource settings. However, cost-effectiveness analyses are needed to empirically provide support to these claims.

HDV prevalence in 25 countries/territories

The number of HBV+ individuals who need to be tested to find one new anti-HDV case can help inform these decisions. This number could be decreased by focusing on the groups and regions that are well known to have a higher probability of anti-HDV+ cases. In countries/territories with a low HBV prevalence, the cost burden of screening for anti-HDV is expected to be low, as the absolute number of individuals who would need to be screened would be relatively small. However, a detailed cost-effectiveness study would be required for countries/territories with a high HBV burden and a low anti-HDV prevalence, such as the East Asian countries presented here.

Concentrating on specific risk groups and regions such as individuals with cirrhosis, the Amazon region, HIV+ individuals,

and immigrants from endemic countries can reduce the number of tests needed to find a positive case. However, recent data has shown that this method can miss upwards of 60% of those infected with HDV.¹⁵

The countries and territories included in the current analysis only represent 37% of the HBV-infected population globally, and the analysis resulted in a much lower anti-HDV prevalence, 2.0%, than previously reported. Expanding these methods to other countries, particularly in sub-Saharan Africa, will be integral to better understanding the burden of HDV globally and thus helping local, regional, and global partners to work towards the elimination of this devastating disease.

Abbreviations

HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HDV, hepatitis D virus.

Financial support

This analysis was funded by a research grant from Gilead Sciences (IN-US-980-6236) and made possible by a grant from John C Martin Foundation (2019-G024). The funders had no role in study design, data collection, data analysis, data interpretation, or preparation of the manuscript.

Conflict of interest

DMR-S, KR-S, AV, and HAR are employees of the CDAF. The CDAF has received funding from the John C Martin Foundation, ZeShan Foundation, The Hepatitis Fund, Gilead Sciences, and AbbVie. AA reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Gilead Sciences, MSD, Sobi, Intercept and Mylan. SA reports payment or honoraria for lectures and educational events from Gilead, AbbVie, MSD, Biogen, not related to this work. TA reports honoraria from consulting for Gilead Sciences, Antios therapeutics, Eiger Biopharmaceutical, Janssen, GSK, and Vir Biotechnology; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead Sciences, Antios therapeutics, Eiger Biopharmaceutical, Janssen, GSK, and Vir Biotechnology; support for attending meetings and/or travel from Gilead Sciences and Abbvie, and advisory board of ENYO. TB reports grants or contracts from Abbvie, BMS, Gilead, MSD/Merck, Humedics, Intercept, Merz, Norgine, Novartis, Orphalan, Sequana Medical; consulting fees from Abbvie, Alexion, Bayer, Gilead, GSK, Eisai, Enyo Pharma, HepaRegeniX GmbH, Humedics, Intercept, Ipsen, Janssen, MSD/Merck, Novartis, Orphalan, Roche, Sequana Medical, SIRTEX, SOBI, and Shionogi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Alexion, Bayer, Gilead, Eisai, Falk Foundation, Intercept, Ipsen, Janssen, MedUpdate GmbH, MSD/Merck, Novartis, Orphalan, Sequana Medica, SIRTEX, and SOBI; and support for attending meetings and/or travel from Gilead, Abbvie, Intercept, Janssen. RB reports grants or contracts from Gilead and Abbvie and consulting fees from Abbvie and Gilead. MRB reports consulting fees from Gilead; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Gilead and EISAI-MSD; support for attending meetings and/or travel from Gilead and AbbVie; participation on a Data Safety Monitoring Board or Advisory Board from Roche, AbbVie, Gilead, Janssen and EISAI-MSD; other financial or non-financial interests from being the coordinator of the working group for the implementation of the resolution (n.397, April 2018) for HCV infection control in Tuscany, Italy. MB reports consulting fees from Gilead, Janssen and Altoimmune and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, Janssen and Altoimmune. JC reports grants or contracts, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, support for attending meetings and/or travel and participation on a Data Safety Monitoring Board or Advisory Board from Gilead and Abbvie and leadership or fiduciary role in AEEH – Spanish Association for the Study of the Liver and INHSU Prison Network. MFC reports grants or contracts from Gilead; payment or honoraria for lectures, presentations from Gilead; support for attending meetings and/or travel from Gilead. HLYC reports consulting fees from AbbVie, Aligos, Arbutus, Hepion, GSK, Janssen, Merck, Roche, Vir Biotech, Vaccitach, Virion Ther and Gilead; payment or honoraria for lectures, presentations, speakers bureaus, manuscript

writing or educational events from Gilead, Viatrix and Roche; support for attending meetings and/or travel from Gilead and AbbVie. HC reports honoraria for lectures from Gilead and support for attending meetings including travel from Gilead. PJC reports Grants or contracts from the Ministry of Education Taiwan and the National Science and Technology Council Taiwan. WLC reports consulting fees from Gilead, AbbVie, BMS and PharmaEssenti. CC reports grants or contracts from Gilead Sciences and Janssen Pharmaceuticals; consulting fees from Roche Pharmaceuticals and Altimmune Pharmaceuticals; payment or honoraria for a lecture by Gilead Sciences; patents planned, issued or pending including International Patent PCT/CA2021/050234 polypeptides directed against viral infection and uses thereof and US Patent 17/425,791 polypeptides directed against viral infection and uses thereof; participation on a Data Safety Monitoring Board or Advisory Board from Gilead Sciences; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid as Canadian Association for the Study of the Liver President-Elect (unpaid); receipt of research materials from Gilead Sciences. MC reports consulting fees from Abbvie, Gilead, MSD Sharp&Dohme, GSK, Janssen-Cilag, and Spring Banks Pharmaceuticals Advisory Boards; payment for lectures from Abbvie, Gilead, MSD Sharp&Dohme, and Falk; travel support from Abbvie; advisory board member for Novartis; and German Liver Foundation Scientific Secretary and European Association for the Study of The Liver Governing Board 2018, 2019, 2020. AC reports consulting fees and honoraria for lectures from Abbvie, Gilead Sciences and MSD. JC reports research support from Gilead Sciences, AbbVie, MSD and Intercept Pharmaceuticals; consulting fees from Gilead, Abbvie, Intercept, Shionogi; speaker for Gilead Sciences, Rubio, Intercept, Amgen and AbbVie; travel support from Gilead and Abbvie; serving as the president of SEPD; and receipt of materials from Echosens. VdL reports grants, consulting fees, speaker honoraria, and travel support from Gilead & Abbvie. ASD reports payment for lectures from Gilead and MSD. OE reports consulting fees from Eiger Biopharmaceuticals; speaker honoraria from Gilead, Abbvie, Neopharm; travel support from Abbvie; advisory board of HepQuant LLC; and serving as Secretary, Israeli Society for the study of liver diseases. XF reports grants or contracts from Instituto Carlos III, Ministerio Sanidad, España; consulting fees from Affirma and Gilead; Payment or honoraria for speaking from Gilead and participation on a Data Safety Monitoring Board or Advisory Board for Novartis. GF reports consulting fees from GSK, Biomarin and Pfizer; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Biomarin, Abbvie and CSL Behring; and participation on a Data Safety Monitoring Board or Advisory Board for GSK. JGS reports consulting fees and speaker honoraria from Gilead Sciences. PG reports speaking and consulting honoraria from Gilead Sciences. RG reports grants/research support from Gilead; Consultant and/or Advisor to Abbott, AbbVie, Altimmune, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, Venatorx; Current Activity with Scientific or Clinical Advisory Boards: AbbVie, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Prodigy; Current Clinical Trials Alliance: Topography Health; Chair Clinical Advisory Board: Prodigy; Advisory Consultant: Diagnostic Companies: Fibronostics, Fujifilm/Wako, Perspectrum, Quest, Sonic Incytes; Data Safety Monitoring Board: Arrowhead, CymaBay Therapeutics, Durect; speaker's contract to do promotional talks for AbbVie, AstraZeneca, BMS, Eisai, Genentech, Gilead Sciences Inc. and Intercept; minor stock shareholder (liver space noted only): RiboSciences, CoCrystal and Stock Options: Eiger, Genlantis, HepQuant, AngioCrine and HepaTx. JSG reports Founder, Board of Directors Eiger BioPharmaceuticals, Inc.; and stock or stock options from Eiger BioPharmaceuticals, Inc. SH reports participating on the

advisory board for the Sofosbuvir plus Ravidasvir Trial. JH reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie and Gilead. YCH reports grants and contracts from Taiwan's National Science and Technology Council, Gilead Sciences, E-Da Hospital, Stanford University, and Tomorrow Medical Foundation; honoraria for speaking from Gilead Sciences, Roche, Abbvie, & BMS; travel support from Abbvie and Gilead Sciences; and advisory board participation for Gilead Sciences. DJ reports grants or contracts from Hoffmann La Roche and GlaxoSmithKline for Principal Investigator fee for participation in International Multicenter Clinical Trial; support for attending the International Liver Congresses 2022 and 2023 from Angelini Pharma. MK reports a Gilead Fellowship 2020 that was paid to their institution and speaker honoraria from Nordic Drugs, Gilead, and MSD/Merck. LK reports consulting fees from Abbvie; speaking honoraria and support for travel from Abbvie and Gilead Sciences. PL reports honoraria for speaking from BMS, Roche, Gilead Sciences, GSK, Abbvie, MSD, Arrowhead, Alnylam, Janssen, Vir, Sbring Bank, MYR, Eiger, Antios, and Aligos. JVL reports grants from AbbVie, Gilead Sciences and MSD to their institution; consulting fees from AbbVie and Gilead Sciences; honoraria for speaking from AbbVie, Gilead Sciences, Intercept, Janssen, MSD, Novo Nordisk; advisory board participation for AbbVie; and serving the EASL International Liver Foundation as Vice-chair, HIV Outcomes Co-chair, EuroTest Steering Committee member, all unpaid. GM reports leadership or fiduciary role as WGO President. RTM reports consulting fees, travel support and participation on advisory boards for AbbVie, Gilead, and Bayer. ASMM reports grants or contracts from Gilead Sciences and Abbvie for speaking for scientific purposes in medical reunions. QN reports consulting fees from Gilead, MSD, Novartis, BMS, Roche & GSK. CO reports support from American Association for the Study of the Liver: Invited speaker at the North American Viral Hepatitis Elimination Summit, March 24-25, 2023, Reimbursement payment made to Govt. of Canada; International Plasma and Fractionation Association (IPFA): Invited speaker at the IPFA/Paul Ehrlich Institute 29th International Workshop on Surveillance and Screening of Blood-borne Pathogens, May 10-11, 2023, Reimbursement payment made to Govt. of Canada. CQP reports research grants and honoraria for lectures from Gilead Sciences paid to their institution. MGP reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead and leadership or fiduciary role as Second Vice President of ALEH – Latin-American Association for Study of Liver Disease. AR reports grants or contracts from Abbvie, Gilead, Intercept and Merck; consulting fees from Abbvie, Gilead and Intercept; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, Gilead, Intercept, Amgen, Novo-Nordisk and Novartis; participation on a Data Safety Monitoring Board or Advisory Board for Abbvie, Gilead, Intercept, Janssen, Novo-Nordisk and Novartis; and stock or stock options from Abbvie. JPR reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Astra-Zeneca, Advanz, Abbvie, Gilead and Eisai; participation on a Data Safety Monitoring Board or Advisory Board for Roche, Advanz and Astra Zeneca; and leadership or fiduciary role in APEF. SdFR reports consulting fees from the World Health Organization and leadership or fiduciary role as Vice-President/President (from November 2022) of EUPHA Section on Public Health Policy and Politics (unpaid). MR reports consulting fees from Gilead Sciences; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead Sciences and Abbvie; and support for attending meetings and/or travel from Gilead Sciences. WR reports grants or contracts from NIHR Health Protection Research Unit and MRC Stratified Medicine Grant; payment for speaking from Siemens Healthineers and stock or stock options from Qur Limited as the founder with <10% stock. MDR reports travel support from Gilead. CS reports honoraria for lectures for Gilead and BMS; payments for advisory boards from Gilead; and unpaid board member of the German Society of Internal Medicine (DGIM), the German Patient Association Deutsche Leberhilfe and the German Liver Association Deutsche Leberstiftung. WKS reports research grants paid to their institution from Gilead, Pfizer, Alexion Pharmaceutical, Ribo Life Sciences, Boehringer Ingelheim; consulting fees from Gilead & Abbot; and honoraria for lectures from Gilead, AstraZeneca, Abbott. DS reports consulting fees from VBI Vaccines Inc, and advisory board member of the Viral Hepatitis Prevention Board, Belgium. FT reports grants paid to their institution from Allergan, BMS, Inventiva, Gilead; consulting fees from Allergan, Bayer, Gilead, BMS, Boehringer, Intercept, Ionis, Inventiva, Merz, Pfizer, Alnylam, NGM, CSL Behring, Novo Nordisk, Novartis; honoraria for lectures from Gilead, AbbVie, Falk, Merz, Intercept; payment for expert testimony from Alnylam; travel support from Gilead; and advisory board for Pfizer. NT reports grants from Gilead, Genentech, Roche; consulting fees from EXIGO Mgmt LLC, ENYO, PPD Pharma; and honoraria for speaking from the University of Maryland. GLHW reports grants from Gilead Sciences; consulting fees from Gilead Sciences and Janssen, and honoraria for speaking from Abbott, Abbvie, Bristol-Myers Squibb,

Echosens, Furui, Gilead Sciences and Roche. VWSW reports grants paid to their institution from Gilead Sciences; consulting fees from 3V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Inventiva, Merck, Novartis, Novo Nordisk, Pfizer, ProSciento, Sagimet Biosciences, TARGET PharmaSolutions, Terns; travel support to their institution from Gilead Sciences and AbbVie; honoraria for speaking from Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk; serving pro bono as a Member of the Steering Committee on Prevention and Control of Viral Hepatitis, Council Member of the Hong Kong Association for the Study of Liver Diseases; and cofounder of Illuminatio Medical Technology Limited. TCFY reports consulting fees, honoraria for speaking and travel support from Gilead Sciences. MLY reports grants from Abbott, Abbvie, BMS, Gilead, Merck and Roche diagnostics; consulting fees from Abbvie, Abbott, BMS, Gilead, Merck, PharmaEssentia, Roche and Roche diagnostics; honoraria for speaking from Abbvie, Abbott, BMS, Eisai, Eli Lilly, Gilead, IPSEN, Merck, Ono, Roche and Roche diagnostics; travel support from Abbvie, Abbott, Gilead, and Roche diagnostics; and serving on Taiwan Association for the Study of the Liver (TASL). CY reports consulting fees paid to their institution from Gilead Biopharma; honoraria for speaking from Roche Biopharma, Eiger Biopharma, and Gilead Biopharma; travel support to institution from AbbVie Biopharma and Gilead Biopharma; and unpaid advisory board for Eiger Biopharma.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

DMR-S and HR conceived the study. DMR-S designed the methodology and was responsible for project administration. DMR-S and HR supervised the study. DMR-S, HR, and KR-S did the formal analysis. HR acquired funding. DMR-S was responsible for data visualization. DMR-S and HR wrote the original draft. DMR-S, HR, and KR-S had access to the underlying data and models. DMR-S, KR-S, HC, ASV, and HR accessed and verified the data. All authors curated data. All authors validated data. All authors reviewed and edited the manuscript. All authors had full access to the data for their country and accepted responsibility to submit for publication.

Data availability statement

The sources of all underlying data and modeling assumptions can be found in the Supplementary Materials. These data can also be found at The Polaris Observatory, <https://cdfound.org/dashboard/polaris/>. For additional inquiries please contact the authors within 1 year of publication.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2023.10.043>.

References

- [1] Polaris Observatory Collaborators. The global prevalence, cascade of care and prophylaxes coverage of hepatitis B in 2022: a modeling study. *Lancet Gastroenterol Hepatol.* 2023;8(10):879–907.
- [2] Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. *Lancet* 2011;378(9785):73–85.
- [3] Kamal H, Fornes R, Simin J, et al. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: a systematic review and meta-analysis of longitudinal studies. *J Viral Hepat* 2021;28(10):1431–1442.
- [4] Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. *J Viral Hepat* 2011;18(6):434–442.
- [5] Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. *J Hepatol* 2010;53(5):834–840.
- [6] Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). *Gut* 2000;46(3):420–426.
- [7] Beguelin C, Moradpour D, Sahli R, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. *J Hepatol* 2017;66(2):297–303.
- [8] Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. *J Infect Dis* 2020;221(10):1677–1687.
- [9] Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. *J Hepatol* 2020;73(3):523–532.
- [10] Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. *Gut* 2019;68(3):512–521.

HDV prevalence in 25 countries/territories

- [11] Miao Z, Pan Q. Revisiting the estimation of hepatitis D global prevalence. *J Hepatol* 2020;73(5):1279–1280.
- [12] Stockdale AJ, Hutin Y, Geretti AM. Reply to: "Revisiting the estimation of hepatitis D global prevalence". *J Hepatol* 2020;73(5):1280–1281.
- [13] Stockdale AJ, Kreuels B, Henrion MRY, Giorgi E, Kyomuhangi I, Geretti AM. Hepatitis D prevalence: problems with extrapolation to global population estimates. *Gut* 2020;69(2):396–397.
- [14] Lazarus JV, Al-Rifai A, Sanai FM, et al. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: a scoping review. *Liver Int* 2023;43 Suppl 1:116–123.
- [15] Palom AR-SA, Vico J, Pacin B, Vargas E, Barreira-Díaz A, Rodríguez-Frías F, Riveiro-Barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. *JHEP Rep* 2022;4(10):1–4.
- [16] Polaris Observatory C. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. *Lancet Gastroenterol Hepatol* 2023;8(10):879–907.
- [17] Kondili LA, Cuko L, Chionne P, et al. Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years. *Eur J Gastroenterol Hepatol* 2010;22(2):167–171.
- [18] Lago BV, Mello FCA, Barros TM, et al. Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody. *J Med Virol* 2018;90(8):1358–1363.
- [19] Andrade AP, Pacheco SD, Silva FQ, et al. Characterization of hepatitis B virus infection in illicit drug users in the Marajo Archipelago, northern Brazil. *Arch Virol* 2017;162(1):227–233.
- [20] Matos MA, Franca D, Carneiro M, et al. Viral hepatitis in female sex workers using the Respondent-Driven Sampling. *Rev Saude Publica* 2017;51:65.
- [21] Ribeiro Barbosa J, Sousa Bezerra C, Carvalho-Costa FA, et al. Cross-sectional study to determine the prevalence of hepatitis B and C virus infection in high risk groups in the northeast region of Brazil. *Int J Environ Res Public Health* 2017;14(7).
- [22] Oliveira MP, Matos MA, Silva AM, et al. Prevalence, risk behaviors, and virological characteristics of hepatitis B virus infection in a group of men who have sex with men in Brazil: results from a respondent-driven sampling Survey. *PLoS One* 2016;11(8):e0160916.
- [23] Tengan FM, Abdala E, Nascimento M, Bernardo WM, Barone AA. Prevalence of hepatitis B in people living with HIV/AIDS in Latin America and the Caribbean: a systematic review and meta-analysis. *BMC Infect Dis* 2017;17(1).
- [24] Zago AM, Machado TF, Cazarim FL, Miranda AE. Prevalence and risk factors for chronic hepatitis B in HIV patients attended at a sexually-transmitted disease clinic in Vitoria, Brazil. *Braz J Infect Dis* 2007;11(5):475–478.
- [25] de Matos MAD, Ferreira RC, Rodrigues FP, et al. Occult hepatitis B virus infection among injecting drug users in the Central-West Region of Brazil. *Memórias do Instituto Oswaldo Cruz* 2013;108(3):386–389.
- [26] Fernandes FR, Mousquer GJ, Castro LS, et al. HIV seroprevalence and high-risk sexual behavior among female sex workers in Central Brazil. *AIDS Care* 2014;26(9):1095–1099.
- [27] Lemes PS. Dissertação (mestrado). Goiânia: Federal University of Goiás; 2011.
- [28] Aragão ALED. Prevalência e fatores de risco associados à coinfeção com vírus da hepatite B (HBV) em pacientes HIV positivos no estado do Piauí. 2011.
- [29] Neves ACdM. Co-infecções por HIV/AIDS, treponema pallidum e hepatite B e c entre usuários de um centro de testagem e Aconselhamento. São José do Rio Preto; 2011 2011.
- [30] Ministry of Health. Brazil. Boletim Epidemiológico: Hepatites Virais. 2019.
- [31] Naoumov NV, Gueorgiev A, Ognyanov M, Maleev A. Infection with hepatitis delta virus in patients with fulminant hepatitis B and chronic HBsAg carriers in Bulgaria. *Hepatogastroenterology* 1986;33(2):49–51.
- [32] Cheng HH, Wang D, Minuk GY. The prevalence of antibody to delta virus in western Canada. *Clin Invest Med* 1986;9(3):156–159.
- [33] Osioy C, Swidinsky K, Haylock-Jacobs S, et al. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. *JHEP Rep* 2022;4(5):100461.
- [34] National Microbiology Laboratory of the Public Health Agency of Canada. HDV antibody test requests and results by Canadian province. 2022.
- [35] Shen L, Gu Y, Sun L, et al. Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China. *J Med Virol* 2012;84(3):445–449.
- [36] Alvarado-Mora MV, Fernandez MF, Gomes-Gouvea MS, de Azevedo Neto RS, Carrilho FJ, Pinho JR. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population—how is the epidemiological situation? *PLoS One* 2011;6(4):e18888.
- [37] Ministerio de Salud Colombia. Registro individual de Prestación de Servicios de Salud - RIPS. 2021.
- [38] Instituto Nacional de Salud. Sistema Nacional de Vigilancia en Salud Pública -SIVIGILA. 2021.
- [39] di Filippo Villa D, Cortes-Mancera F, Payares E, et al. Hepatitis D virus and hepatitis B virus infection in Amerindian communities of the Amazonas state, Colombia. *Virol J* 2015;12:172.
- [40] England PH. Annual report from the sentinel surveillance study of BBV testing in England. 2019. p. 2020.
- [41] Servant-Delmas A, Le Gal F, Gallian P, Gordien E, Laperche S. Increasing prevalence of HDV/HBV infection over 15 years in France. *J Clin Virol* 2014;59(2):126–128.
- [42] Hess G, Lange W, Bienzle U, Meyer zum Buschenfelde KH. Delta infection in Germany. *Prog Clin Biol Res* 1987;234:433–434.
- [43] Reinheimer C, Doerr HW, Berger A. Hepatitis delta: on soft paws across Germany. *Infection* 2012;40(6):621–625.
- [44] Liu KSH, Seto WK, Lau EHY, et al. A territorywide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. *J Infect Dis* 2019;219(12):1924–1933.
- [45] Lok AS, Wong A, Sporton S, Lai CL, Liu V, Chung HT. Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. *J Hepatol* 1992;14(2–3):332–334.
- [46] Shirazi R, Ram D, Rakovsky A, et al. Characterization of hepatitis B and delta coinfection in Israel. *BMC Infect Dis* 2018;18(1):97.
- [47] Brancaccio G, Nardi A, Madonia S, et al. The present profile of chronic hepatitis B virus infection highlights future challenges: an analysis of the Multicenter Italian MASTER-B cohort. *Dig Liver Dis* 2019;51(3):438–442.
- [48] Stroffolini T, Ciancio A, Furlan C, et al. Migratory flow and hepatitis delta infection in Italy: a new challenge at the beginning of the third millennium. *J Viral Hepat* 2020;27(9):941–947.
- [49] Kondili L. Le caratteristiche epidemiologiche dei pazienti con Epatite D in Italia. Congresso Nazionale Società Italiana di Malattie Infettive e Tropicali. 2021. Milano, Italy.
- [50] Arakawa Y, Moriyama M, Taira M, et al. Molecular analysis of hepatitis D virus infection in Miyako Island, a small Japanese island. *J Viral Hepat* 2000;7(5):375–381.
- [51] Kim HS, Kim SJ, Park HW, et al. The seroprevalence and clinical significance of hepatitis D virus infection in Korean chronic hepatitis B patients. *Hepatol Int* 2011;5(1):203–204.
- [52] Ayala Gaytan JJ, Casillas Romo A, Romero Gonzalez MC. [Frequency of D virus markers at a specialty hospital]. *Rev Gastroenterol Mex* 1989;54(2):83–86.
- [53] Delgersaikhan Zulkhuu Od B, Otgonbayar B, Dashdorj N, Yagaanbuyan D, Dashdorj N. Prevalence of HDV infection in Mongolia. Falk symposium 199. Reiburg, Germany: Karger; 2016.
- [54] Mumtaz K, Hamid SS, Adil S, et al. Epidemiology and clinical pattern of hepatitis delta virus infection in Pakistan. *J Gastroenterol Hepatol* 2005;20(10):1503–1507.
- [55] Velosa J, Ramalho F, Serejo F, Marinho R, de Moura MC. [Chronic hepatitis: the etiological spectrum. The implications for treatment]. *Acta Med Port* 1993;6(6):233–238.
- [56] Gheorghie L, Csiki IE, Iacob S, et al. Hepatitis delta virus infection in Romania: prevalence and risk factors. *J Gastrointestin Liver Dis* 2015;24(4):413–421.
- [57] Jamjoom GA, El-Daly MM, Azhar EI, et al. Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: a single-center study. *Saudi J Gastroenterol* 2017;23(3):176–182.
- [58] Palom A, Rodríguez-Tajes S, Navascues CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. *Aliment Pharmacol Ther* 2020;51(1):158–166.
- [59] Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. *J Natl Cancer Inst* 2012;104(10):790–792.
- [60] Lin HH, Lee SS, Yu ML, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. *Hepatology* 2015;61(6):1870–1879.
- [61] Lee KC, Lin CL, Hsu CW, et al. Decreasing seroprevalence of anti-hepatitis D virus antibodies in the antiviral era with inverse association with hepatitis B virus DNA, Taiwan, 2006 to 2019. *J Med Virol* 2020;92(1):124–127.

- [62] Lee MH, Yang HI, Liu J, et al. Prevalence and risk factors of hepatitis D virus infection: the REVEAL-HBV/HCV/HDV study. *Hepatology* 2014;8(1):S359–S360.
- [63] Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. *Clin Microbiol Infect* 2015;21(11):1020–1026.
- [64] Mese S, Nergiz S, Tekes S, Gul K. Seroprevalence of serum HBSAg positivity and hepatitis delta virus infection among blood donors in Southeastern Turkey. *Clinica Terapeutica* 2014;165(2):95–98.
- [65] Njei B, Do A, Lim JK. Prevalence of hepatitis delta infection in the United States: national health and nutrition examination Survey, 1999–2012. *Hepatology* 2016;64(2):681–682.
- [66] Roberts H, Kruszon-Moran D, Ly KN, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. Households: national health and nutrition examination Survey (NHANES), 1988–2012. *Hepatology* 2016;63(2):388–397.
- [67] Safaie P, Razeghi S, Rouster SD, Privitera I, Sherman KE. Hepatitis D diagnostics: Utilization and testing in the United States. *Virus Res* 2018;250:114–117.
- [68] Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: prevalence, risk factors, and outcomes. *J Hepatol* 2015;63(3):586–592.
- [69] World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva, Switzerland: World Health Organization; 2022.
- [70] Negro F. Hepatitis D virus coinfection and superinfection. *Cold Spring Harb Perspect Med* 2014;4(11):a021550.
- [71] Razavi HA, Buti M, Terrault NA, et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. *J Hepatol* 2023;79(2):576–580.